



STATE MEDICAID DUR BOARD MEETING
 THURSDAY, November 13, 2014
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 125

MINUTES

Board Members Present:

Tony Dalpiaz, PharmD.
 Mr. Kumar Shah
 Keith Tolman, M.D.
 Jay Aldus, DDS

Jennifer Brinton, MD
 George Hamblin, PharmD
 Susan Siegfried, M.D

Board Members Excused:

Mark Balk, PharmD.
 Kyle Jones, M.D.

Michael Symond, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D
 Trevor Smith C.Ph.T.
 Heather Santacruz, R.N.
 Lisa Hunt, R.Ph.

Tim Morley, R.Ph.
 Merelynn Berrett, R.N.
 Richard Sorenson, R.N.

Other Individuals Present:

Mike Broadhead, Abbvie
 Joanita Lake, UofU
 Robert Nahower, UofU
 Lori Howarth, Bayer
 Cody Ball, Select Health
 Caroline Kicklighter, Novartis

Greg Gittus, Alkermes
 Christina Brown, UofU
 Cameron Hill, UofU
 Scott Larson, BMS
 Clayne Garrett, BI
 Bryan Larson, UofU

Meeting conducted by: Tony Dalpiaz, Pharm.D.

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there are no petitions for the board today.
3. **P&T Committee report** – Lisa Hunt addressed the board and showed what the future agenda is for P&T committee discussion. She said that the November meeting is scheduled to discuss Amebicide agents. She said the December meeting is canceled.

4. **Approval of prior meeting minutes** – George Hamblin made a motion to approve the meeting minutes pending the two grammatical issues noticed by Keith Tolman. Jay Aldous seconded the motion. All in favor.
5. **Rheumatoid Arthritis Agents (DMARDS and Anti-TNF Biologic agents)** – Bryan Larson and Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about RA drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.
6. **Public Comment** - none
7. **Board Discussion**
 - a. Robyn Seely presented data from the Utah Medicaid ACOs, including the Prior Authorization requirements for RA drugs. She also shared information about the preferred/non preferred status and clinical PA requirements of the drugs on Fee for Service Medicaid.
 - b. Robyn said that on current criteria, the requirement for a count of the number of swollen or tender joints is not needed any longer with new data presented from the DRRC.
 - c. Robyn Seely also said that another possible change could be a trial period of three months on the agents as well.
 - d. Jennifer Brinton made a motion to remove the bullet point about the swollen or tender joints and to modify bullet point number three, to change ‘or’ to ‘at least’ which would make a trial of a DMARD or second line drug a requirement. This motion would apply to all clinical prior authorizations discussed. George Hamblin seconded the motion. All in favor.
 - e. George Hamblin said that the three month time frame should be left to the doctor to investigate and prescribe accurately.
 - f. Jennifer Brinton asked if the flow chart should be included in the PA to assist providers with knowing what medication should be used. It was determined that the consultation with the Rheumatologist would take care of proper usage.
 - g. There were no petitions for the November meeting.
8. **Meeting Adjourned** – Keith Tolman made a motion to close the meeting. Tony Dalpiaz seconded. All in favor.

The next DUR Board meeting is scheduled for Thursday, December 11th. Rheumatoid Arthritis biologic treatments will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov